Latest From Yale University
Just two weeks after agreeing on a merger with Bristol, Celgene is back at its own deal-making, signing cancer-focused R&D pacts with Kyn and Obsidian. Boehringer and Bioharmony collaborate on novel therapies for hospital-acquired infections, while Sanofi teams with Biomunex on bi- and multi-specific antibodies.
In tandem with Roivant, Cincinnati Children’s launches spinout Aruvant focused on hematologic disorders and separately teams with BridgeBio on genetic disease therapies. Roivant spinout Axovant licenses gene therapy candidates from University of Massachusetts.
Emerging Company Profile: Based on discovery research at Yale, NextCure hopes S15 and other novel targets will provide new inroads in immuno-oncology, while much of the field remains focused on PD-1 inhibitors and combinations.
Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.